- 1 Effectiveness and durability of protection against future SARS-CoV-2 infection
- 2 conferred by COVID-19 vaccination and previous infection; findings from the UK
- 3 SIREN prospective cohort study of healthcare workers March 2020 to September 2021
- 5 Authors

- 6 Victoria Hall^{1,2}* FFPH, Sarah Foulkes¹* MSc, Ferdinando Insalata¹* MSc, Ayoub Saei¹ PhD,
- 7 Peter Kirwan^{1,3} BSc, Ana Atti¹ MSc, Edgar Wellington¹ MSc, Jameel Khawam¹ MSc, Katie
- 8 Munro¹ MSc, Michelle Cole¹ DBMS, Caio Tranquillini¹ MD, Andrew Taylor-Kerr¹ MSc,
- 9 Nipunadi Hettiarachchi¹ BSc, Davina Calbraith¹ PhD, Noshin Sajedi¹ MSc, Iain Milligan¹
- 10 MRCP, Yrene Themistocleous MBChB, Diane Corrigan FFPH, Lisa Cromey MFPH,
- Lesley Price^{5,6} PhD, Sally Stewart^{5,6} MSc, Elen de Lacy⁷ MSc, Chris Norman⁸ MSc, Ezra
- Linley¹ PhD, Ashley David Otter¹ PhD, Amanda Semper¹ DPhil, Jacqueline Hewson¹ PhD,
- 13 Silvia D'Arcangelo¹ PhD, the SIREN Study Group-, Meera Chand^{1,9} FRCPath, Colin S
- Brown^{1,2} FRCPath, Tim Brooks¹ FRCPath, Jasmin Islam¹ PhD, Andre Charlett^{1,10,11} PhD,
- 15 Susan Hopkins^{1,2} FRCP.
- 16 *authors contributed equally
- 17 ☐ SIREN study group names provided in supplementary material

18 Author Affiliations:

- 1. UK Health Security Agency
- 20 2. The National Institute for Health Research Health Protection Research (NIHR) Unit in
- 21 Healthcare Associated Infections and Antimicrobial Resistance at the University of
- 22 Oxford
- Medical Research Council Biostatistics Unit, University of Cambridge
- Public Health Agency Northern Ireland
- 5. Glasgow Caledonian University

26 6. Public Health Scotland 27 7. Public Health Wales 8. Health and Care Research Wales 28 9. Guys and Thomas's NHS Trust 29 10. NIHR Health Protection Research Unit in Behavioural Science and Evaluation at 30 University of Bristol in partnership with Public Health England 31 32 11. NIHR Health Protection Research Unit in Immunisation at the London School of 33 Hygiene and Tropical Medicine in partnership with Public Health England 34 35 Corresponding author: 36 Susan Hopkins, Chief Investigator susan.hopkins@phe.gov.uk

ABSTRACT

38

39

41

42

43

44

46

47

48

49

52

53

54

55

56

57

58

59

60

61

62

Background:

40 Understanding the duration and effectiveness of infection and vaccine-acquired SARS-CoV-

2 immunity is essential to inform pandemic policy interventions, including the timing of

vaccine-boosters. We investigated this in our large prospective cohort of UK healthcare

workers undergoing routine asymptomatic PCR testing.

Methods

45 We assessed vaccine effectiveness (VE) (up to 10-months after first dose) and infection-

acquired immunity by comparing time to PCR-confirmed infection in vaccinated and

unvaccinated individuals using a Cox regression-model, adjusted by prior SARS-CoV-2

infection status, vaccine-manufacturer/dosing-interval, demographics and workplace

exposures.

50 Results

Of 35,768 participants, 27% (n=9,488) had a prior SARS-CoV-2 infection. Vaccine coverage

was high: 97% had two-doses (79% BNT162b2 long-interval, 8% BNT162b2 short-interval,

8% ChAdOx1). There were 2,747 primary infections and 210 reinfections between

07/12/2020 and 21/09/2021. Adjusted VE (aVE) decreased from 81% (95% CI 68%-89%)

14-73 days after dose-2 to 46% (95% CI 22%-63%) >6-months; with no significant difference

for short-interval BNT162b2 but significantly lower aVE (50% (95% CI 18%-70%) 14-73 days

after dose-2 from ChAdOx1. Protection from infection-acquired immunity showed evidence

of waning in unvaccinated follow-up but remained consistently over 90% in those who

received two doses of vaccine, even in those infected over 15-months ago.

Conclusion

Two doses of BNT162b2 vaccination induce high short-term protection to SARS-CoV-2

infection, which wanes significantly after six months. Infection-acquired immunity boosted

- 63 with vaccination remains high over a year after infection. Boosters will be essential to
- 64 maintain protection in vaccinees who have not had primary infection to reduce infection and
- transmission in this population.
- 66 Trial registration number
- 67 ISRCTN11041050

BACKGROUND

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Understanding the durability of the immune response to SARS-CoV-2 infection and COVID-19 vaccination remains critical to the global COVID-19 response. Twenty months after emergence, SARS-CoV-2 has caused millions of deaths, and widespread disruption to global health and economies. The development and mass deployment of COVID-19 vaccines within a year was unprecedented and has facilitated relaxation of nonpharmaceutical interventions. COVID-19 vaccines have demonstrated short-term effectiveness in real-world studies, reducing both symptomatic and asymptomatic infection, severity and secondary transmission.²⁻⁵ The duration of this protection over longer periods remains uncertain and requires ongoing study. Population uptake of COVID-19 vaccination in the UK (aged over 12 years) is 80.4% for two doses, and prioritised groups (health and social care workers and the clinically vulnerable). are now over six months after their second dose. Following concerns about potential vaccine waning at this point, 7-11 and in the context of sustained high levels of community infections. 6 the UK Government initiated a roll-out of booster vaccination to priority groups in September 2021.¹² Improved understanding and characterisation of vaccine effectiveness at longer intervals and potential variation by demographic factors, vaccine schedules and history of SARS-CoV-2 infection is urgently required to support global vaccination schedules. The SARS-CoV-2 Immunity and Reinfection Evaluation (SIREN) study, a large cohort of healthcare workers undergoing fortnightly asymptomatic PCR testing, had over 30% of participants testing seropositive at enrolment and is well suited to this task. 5,13,14 In this analysis we estimate the effectiveness and durability of protection against future SARS-CoV-2 infection conferred by previous SARS-CoV-2 infection and COVID-19 vaccination in the SIREN cohort from March 2020 to September 2021.

METHODS

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

Study design and participants The SIREN study is a multicentre prospective cohort of healthcare workers aged over 18 years across the UK. Data sources and measurement Participants undergo fortnightly SARS-CoV-2 PCR testing (supplemented by widespread lateral flow testing), monthly antibody testing and complete regular guestionnaires. This data collection is described elsewhere.5 Vaccination data (manufacturer, dates) were obtained via linkage on personal identifiers from national COVID-19 registries in each health administration and directly from participants in their questionnaires. Dosing interval was categorised as 'short' if dose-two was administered up to 6-weeks post dose-one and 'long' if ≥6-weeks. 15 Serum samples from all participant baseline visits are collected centrally and tested at the United Kingdom Health Security Agency (UKHSA) central testing laboratory at Porton Down using the semi-quantitative Elecsys Anti-SARS-CoV-2 nucleocapsid (N) protein assay and fully quantitative Elecsys Anti-SARS-CoV-2 spike (S) protein assay (Roche Diagnostics). **Outcomes** The primary outcome was a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ≥90 days or one new PCR positive ≥28 days after an antibody positive result consistent with previous infection. Explanatory variables and exclusion criteria Participants were assigned into one of two cohorts at the start of analysis time: participants in the naïve cohort had no history of SARS-CoV-2 positivity and the positive cohort being those who had ever received a PCR positive or antibody result consistent with prior SARS-CoV-2 infection.

Participants were excluded from this analysis if event or cohort assignment could not be accurately completed, i.e. no PCR tests during follow-up, or if they were in the positive cohort but were infected after vaccination or lacked an onset date for primary infection (PCR positive or COVID-symptom onset).

Person time at risk

Follow-up began on 07 December 2020, the day before COVID-19 vaccination was introduced to the UK, and continued until 21 September 2021, covering 10 calendar months. All participants enrolled on or before 07 December 2020 contributed follow-up time from 07 December 2020 onwards. Participants enrolled after 07 December 2020 began contributing follow-up time from their enrolment date (delayed entry). Participants moved from the negative to positive cohort 90 days after a primary PCR positive date, if their primary infection was before vaccination, at which point they were considered at risk of reinfection (mirroring the SIREN reinfection definition: two PCR positives >90-days apart). End of follow-up time for individual participants was either date of primary infection (negative cohort), date of reinfection (positive cohort) or last PCR negative test.

Statistical methods

We used a Cox proportional hazards model with delayed entry, the outcome being time-to-infection with a positive PCR test. The model accounted for the calendar time, varying infection rate via the baseline hazard, that could take any functional form. Analysis time started shortly before the second wave peaked, continuing through Spring 2021 and into the third wave (Supplementary Figure iii), thus, accounting for a varying hazard rate was crucial. The main predictors – vaccine status and previous infection status - were categorical and time-varying. We grouped on the time to vaccination and divided follow-up time into unvaccinated and 24 post-vaccination time intervals, with post-vaccination intervals categorised by manufacturer, dose and dosing interval, the latter to explore differences in protection in those receiving dose two closer in time to their first dose. We also grouped the

time since primary infection into four time-intervals: before primary infection (naïve), and then 3-9 months, 9-15 months and ≥15 months after primary infection. Vaccine effectiveness and protection from primary infection were calculated as 1-HR. We used robust variance estimates to guard against the potential for unmeasured confounders at trust level. We initially fitted a main effects model, with no interactions between vaccine and primary infection status. This was our main model that highlighted vaccine effectiveness over time. We also fitted an interaction model, in which we did not consider time since vaccination, brand and manufacturer, to focus on protection from primary infection over time by vaccine status. We fitted both models with and without additional time invariant covariates: age, ethnicity, co-morbidities, region, frequency of COVID-19 patient contact, patient-facing role, and workplace setting. Independently, we also fitted an equivalent piecewise exponential proportional hazards model. This produced consistent VE results and provided estimates of the baseline hazard rates (supplementary material; Figure iii), analogous to the method we have previously described.⁵ We used STATA software (version 15.1; StataCorp LLC, College Station, TX, USA) for all analyses. Results were independently replicated in R (v. 4.1.1, survival package v.3.2-13). Our annotated code is available (https://github.com/SIREN-study/SARS-CoV-2-Immunity). This study was registered, number ISRCTN11041050, and received approval from the Berkshire Research Ethics Committee on 22 May 2020. Reporting of the study follows the Strengthening the Reporting of Observational studies in Epidemiology guidelines. 16

RESULTS

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

Study population

The SIREN study enrolled 44,546 participants between 18 June 2020 and 23 April 2021 from 135 sites across the UK; n=35,768 met the inclusion criteria for this analysis (Supplementary Figure i). Participants are described in Table 1, and were predominantly

female (84%), with a median age of 46 years (IQR 36-54). We assigned 26,280 participants to the naïve cohort and 9,488 to the positive cohort at analysis start time. The positive cohort were more likely to be male, younger, from Black, Asian and ethnic minority backgrounds, work in clinical roles and report more frequent exposure to COVID-19 patients (Table 1). By the end of analysis time, 97% of the cohort had received two vaccine doses: 78.5% BNT162b2 long-interval, 8.6% BNT162b2 short-interval and 7.8% ChAdOX1 (Table 1, Supplementary Figure ii). We identified no major demographic differences between participants by vaccine schedule (Supplementary Table i). Follow-up time varied by participant, with a total of 7,482,388 participant person-days, of which there were 998,270 person-days unvaccinated, and 6,430,118 person-days vaccinated (from date of first dose). There were 60,301 PCR tests performed in the unvaccinated follow-up period and 443,979 PCR tests in the vaccinated follow-up period, with an average test interval of 16.6 days per test in the unvaccinated period and 14.5 days per test in the vaccinated period. There were 2,747 primary infections during follow-up and 210 reinfections, with cases peaking at the end of December 2020 and declining by March-April 2021, before increasing in May 2021, which mirrored national trends (Supplementary Figure iii).

Vaccine effectiveness

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

The overall adjusted vaccine effectiveness (aVE) against infection following dose-two of BNT162b2 vaccine administered after the long-interval was 81% (95% CI 68%-89%) in the first two months after the development of the full immune response (14-73 days after second dose) (Table 2, Figure 1). aVE declined over time, although remained high at 70% (95% CI 62%-76%) 4-6 months after dose-two. After six months we saw evidence of waning, with aVE of 46% (95% CI 22%-63%).

A similar trend was observed for BNT162b2 dose two short-interval, with higher protection at 14-73 days (aVE 86% (95% CI 73%-93%) decreasing to 61% (95% CI 45%-73%) after 6-months. We found no significant difference in protection after dose-two between BNT162b2

long and short inter-vaccination intervals, with HR for infection of 1.39 (95% CI 0.64-3.00, p=0.41) using short interval as the reference group.

For ChAdOX1, aVE from two doses was 50% (95% CI 16%-69%) 14-73 days after second dose. Effectiveness did not fall significantly after longer intervals after dose-two, with overlapping confidence intervals of VE reflecting the small number of participants contributing to this estimate (Table 2, Figure 1). Compared to ChAdOX1, we found that Pfizer short was 72% more effective (95% CI 38%-88%, p=0.002) and Pfizer long was 62% more effective (95% CI 26%-80%, p=0.004), in the interval 14-73 days.

Durability of protection following primary infection

In contrast, looking at the impact of vaccination on the cohort with prior COVID-19 infection (positive cohort), using naïve unvaccinated as the reference group (Table 3, Figure 2), a beneficial boosting of infection-acquired immunity was apparent, with combined protection over 90% a year or more after primary infection and two doses of vaccination. There was no evidence of the protection afforded by primary infection waning in participants who had received two doses of vaccine up to 15 months after the primary infection. A similar trend was observed after a single dose and even without vaccination, however, most unvaccinated follow-up time occurred pre-Delta.

DISCUSSION

Eighteen months after the emergence of SARS-CoV-2 and ten months after the rapid deployment of COVID-19 vaccines, we have assessed the durability of protection from SARS-CoV-2 infection conferred by both infection-acquired and vaccine-acquired immunity. Our cohort of 35,768 healthcare workers, including over a quarter with prior infection, primarily received two doses of BNT162b2 administered at a long inter-vaccine interval, which induced high levels of protection over the first 6 months, peaking between 68% and 89% in the first two months; however, we found evidence of significant waning, with protection reducing to between 22% and 63% after six months. We found no difference in

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

protection following two doses when comparing BNT162b2 short interval with BNT162b2 long interval, although we found significantly lower protection from two doses of ChAdOX1 compared to BNT12b2. Of note, the period of waning coincided with the Delta variant being the predominant circulating strain, which may account for the more pronounced waning of protection in our cohort, given the reduced vaccine effectiveness against Delta reported.¹⁷ Delivery of vaccination to individuals after prior infection effectively boosts and extends their immunity, with participants who received two doses of vaccination after infection emerging as the most highly protected group in our cohort for both symptomatic and asymptomatic infection, with similar protection to that provided by a three-course vaccination against symptomatic infection.¹⁸ Our finding of reduced protection from infection following two doses of vaccination after six months strengthens the accruing evidence base. Our design overcomes several biases of recent studies, including underestimation of the proportion with prior infection; ¹⁹ previous studies have typically investigated symptomatic infection and utilised test-negative casecontrol or retrospective cohort designs using national testing surveillance data.^{7,9,11} We note that these real-world studies have found consistently lower protection and more pronounced waning than the recent BNT162b2 clinical trial, which reported vaccine efficacy against symptomatic infection of 83.7% (95% CI, 74.7 to 89.9) 4-6 months after dose-2.20 likely related to the reduced vaccine effectiveness reported against the Delta variant.¹⁷ The significantly lower protection observed in this study after ChAdOX1 compared to BNT162b2 has also been found in other recent studies. 7,20 Several studies have observed lower antibody titres following ChAdOx1 vaccination than BNT162b2, 21,22 and a shorter interval to fall below a protective antibody threshold from this lower baseline has been proposed as a causal mechanism for the lower vaccine effectiveness. 20 We found no evidence of a difference in protection against infection after two doses of BNT162b2 between short and long-interval. This is despite evidence of significantly higher antibody, B cell and T cell responses in recipients of long-interval compared to short-interval vaccination

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

regimens, 15,23,24 and higher VE against symptomatic infection from one observational study. 15 Plausibly the threshold to prevent all infections may be lower than that for symptomatic infection. Studies to date have shown more durable protection against severe outcomes of hospitalisation and death following vaccination.^{7,25} Whilst we have estimated VE against all infections, including asymptomatic infections that have limited clinical impact, a reduction in VE against infection will increase transmission and risk of infection to high-risk individuals, some of whom will progress to severe disease. To our knowledge, this study reports the longest real-world follow-up time from primary infection to date. It remains unclear how long immune protection will last after previous infection due to the limited length of follow-up period, however modelling has suggested that protection could last for up to 61 months. 21,26 In our cohort, we have demonstrated that protection from primary infection can last up to 15 months in some individuals, while other studies have reported protection ranging from 5-12 months. 27-29 Our ability to study infectionacquired immunity in unvaccinated individuals at longer intervals is now limited given the very small number of our cohort remaining unvaccinated. It is important to highlight that most follow-up without vaccination in the 9-15-month category occurred in the pre-Delta wave. It is possible that the sustained infection-acquired protection in our cohort is affected by repeated low dose occupational exposure to COVID-19,30 and therefore less generalisable to populations at lower exposure. It is also possible that this results from a broader diversity of T-cell immunity against different SARS-CoV-2 spike protein epitopes emerging following infection, enhancing protection against variants and inducing long-lasting memory T-cell populations. 27,31,32 Although our finding of greater protection following infection-acquired immunity has been demonstrated by other authors. 33,34 others have reported vaccine-acquired immunity to be equivalent, 35,36 or superior. The high protection provided by infection-acquired immunity, we have demonstrated additional benefit from vaccination in previously infected participants, in line with previous studies. 34,38,39 Until

thresholds for protective antibody titres against SARS-CoV-2 infection are established, it is challenging to accurately estimate how much vaccine-induced immunity is required to prevent reinfection at an individual level. Key strengths of our study are the size of our cohort, asymptomatic testing and testing frequency, with an average PCR test interval of 16.6 days in unvaccinated time and 14.5 days per test in vaccinated follow-up time, supplemented by the widespread use of lateral flow testing, which means we can be confident that most infections were detected. As a well-defined cohort, we can simultaneously investigate vaccination and prior infection status and adjust for important confounders, including workplace exposures. The most important limitation of our study is the relatively small number of participants continuing to contribute follow-up time to key vaccination exposures: unvaccinated, ChAdOx1 and BNT162b2 short interval. This particularly affects the precision of estimates and our ability to assess potential waning following two-doses of ChAdOx1, and >15 months after primary infection in unvaccinated participants. We consider that the strengths of our study design and speed of vaccine deployment significantly limit the impact of depletion-of-susceptible bias (which particularly affects studies on vaccine-waning), 19 however we recognise some residual confounding may remain. Conclusion

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

Two doses of BNT162b2 vaccination, given with a short or long-interval, induce high protection to SARS-CoV-2 infection (asymptomatic and symptomatic) in the short-term, but this protection wanes after six months, during a period where Delta predominates. Protection provided from two doses of ChAdOX1 is considerably lower overall. The highest and most durable protection is observed in those with hybrid immunity, who received one or two doses of vaccine after a primary infection; this will be important for the deployment of vaccines in highly exposed and immune populations. Strategic use of booster vaccine doses to avert waning of protection (particularly in double vaccinated naïve individuals) is

essential to provide reduced infection, and therefore transmission in the ongoing global response to COVID-19.

Acknowledgements

We would like to thank all participants for their ongoing contribution and commitment to this study, and to all the research teams for their hard-work and support delivering the study at all 135 sites. Thank you all for making SIREN possible.

We are grateful to colleagues at the UKHSA Seroepidemiology Unit for their support biobanking and processing the high-volumes of serum samples and to colleagues at UKHSA Porton Down who have organised and performed all the centralised serology testing, including testing 35,000 baseline samples, in particular Caoimhe Kelly, Anaya Ellis, Gabrielle Harker, Olivia Carr, Aaron Lloyd, Hannah Selman, Matthew Royds and Georgia Hemingway.

References

- 319 1. Our World in Data. Coronavirus (COVID-19) Deaths Statistics and Research. 2021. (Accessed
- 320 24/11/2021, 2021, at https://ourworldindata.org/covid-deaths.)
- 321 2. Department of Health. Chapter 14a COVID-19 SARS-CoV-2. 2021. The Green Book.
- 322 (Accessed 02/11/2021, 2021, at
- 323 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment data/file
- 324 /984310/Greenbook chapter 14a 7May2021.pdf)
- 325 3. Department of Health. Optimising the COVID-19 vaccination programme for maximum
- 326 short-term impact. GOV.UK, 2021. (Accessed 02/11/2021, 2021, at
- 327 https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-
- 328 <u>statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact.</u>)
- 329 4. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-
- 330 AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older
- adults in England: test negative case-control study. BMJ 2021;373:n1088-n.
- 332 5. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England
- and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre,
- 334 cohort study. Lancet 2021;397:1725-35.
- 335 6. UK Health Security Agency. Coronavirus (COVID-19) in the UK. 2021. (Accessed 01/11/2021,
- 336 2021, at https://coronavirus.data.gov.uk/details/vaccinations.)
- 337 7. Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of
- 338 Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv
- 339 2021:2021.09.15.21263583.
- 340 8. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up
- to 6 months in a large integrated health system in the USA: a retrospective cohort study. The Lancet
- 342 2021;398:1407-16.

- 343 9. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against
- 344 SARS-CoV-2 Infection in Qatar. New England Journal of Medicine 2021.
- 345 10. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19
- Vaccine over 6 Months. New England Journal of Medicine 2021.
- 347 11. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in
- 348 Israel. New England Journal of Medicine 2021.
- 349 12. Department of Health. COVID-19 vaccination: a guide to booster vaccination. 2021.
- 350 (Accessed 02/11/2021, 2021, at https://www.gov.uk/government/publications/covid-19-
- 351 vaccination-booster-dose-resources/covid-19-vaccination-a-guide-to-booster-vaccination.)
- 352 13. Wallace S, Hall V, Charlett A, et al. SIREN protocol: Impact of detectable anti-SARS-CoV-2 on
- 353 the subsequent incidence of COVID-19 in 100,000 healthcare workers: do antibody positive
- 354 healthcare workers have less reinfection than antibody negative healthcare workers? medRxiv
- 355 2020:2020.12.15.20247981.
- 356 14. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive
- 357 compared with antibody-negative health-care workers in England: a large, multicentre, prospective
- 358 cohort study (SIREN). The Lancet 2021;397:1459-69.
- 359 15. Amirthalingam G, Bernal JL, Andrews NJ, et al. Higher serological responses and increased
- 360 vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19
- 361 in England. medRxiv 2021:2021.07.26.21261140.
- 362 16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
- 363 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
- 364 guidelines for reporting observational studies. The Lancet 2007;370:1453-7.
- 365 17. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the
- 366 B.1.617.2 (Delta) Variant. N Engl J Med 2021;385:585-94.

- 367 18. Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay M, Bernal JL. Effectiveness of BNT162b2
- 368 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in
- 369 England: test negative case-control study. medRxiv 2021:2021.11.15.21266341.
- 370 19. Lipsitch M, Goldstein E, Ray GT, Fireman B. Depletion-of-susceptibles bias in influenza
- vaccine waning studies: how to ensure robust results. Epidemiol Infect 2019;147:e306-e.
- 372 20. Aldridge RW, Yavlinsky A, Nguyen V, et al. Waning of SARS-CoV-2 antibodies targeting the
- 373 Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk
- of breakthrough infections: analysis of the Virus Watch community cohort. medRxiv
- 375 2021:2021.11.05.21265968.
- 376 21. Wei J, Pouwels KB, Stoesser N, et al. SARS-CoV-2 anti-spike IgG antibody responses after
- 377 second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general population.
- 378 medRxiv 2021:2021.09.13.21263487.
- 379 22. Parry H, Bruton R, Stephens C, et al. Differential immunogenicity of BNT162b2 or ChAdOx1
- 380 vaccines after extended-interval homologous dual vaccination in older people. Immun Ageing
- 381 2021;18:34.
- 382 23. Payne RP, Longet S, Austin JA, et al. Immunogenicity of standard and extended dosing
- 383 intervals of BNT162b2 mRNA vaccine. Cell 2021;184:5699-714.e11.
- 384 24. Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination enhances peak
- antibody generation in older people. medRxiv 2021:2021.05.15.21257017.
- 386 25. Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and
- 387 Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults United States,
- 388 March-July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1156-62.
- 389 26. Townsend JP, Hassler HB, Wang Z, et al. The durability of immunity against reinfection by
- 390 SARS-CoV-2: a comparative evolutionary study. The Lancet Microbe 2021.
- 391 27. Milne G, Hames T, Scotton C, et al. Does infection with or vaccination against SARS-CoV-2
- lead to lasting immunity? The Lancet Respiratory Medicine.

- 393 28. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth
- against SARS-CoV-2 one year after infection. Nature 2021;595:426-31.
- 395 29. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection
- against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a
- 397 population-level observational study. The Lancet 2021;397:1204-12.
- 398 30. Swadling L, Diniz MO, Schmidt NM, et al. Pre-existing polymerase-specific T cells expand in
- abortive seronegative SARS-CoV-2. Nature 2021.
- 400 31. Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. The
- 401 Lancet Infectious Diseases.
- 402 32. Jagannathan P, Wang TT. Immunity after SARS-CoV-2 infections. Nature Immunology
- 403 2021;22:539-40.
- 404 33. Satwik R, Satwik A, Katoch S, Saluja S. ChAdOx1 nCoV-19 effectiveness during an
- 405 unprecedented surge in SARS COV-2 infections. European Journal of Internal Medicine 2021;93:112-
- 406 3.
- 407 34. Gazit S, Shlezinger R, Perez G, et al. Comparing SARS-CoV-2 natural immunity to vaccine-
- 408 induced immunity: reinfections versus breakthrough infections. medRxiv
- 409 2021:2021.08.24.21262415.
- 410 35. Lumley SF, Rodger G, Constantinides B, et al. An Observational Cohort Study on the
- 411 Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7
- 412 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. Clinical Infectious
- 413 Diseases 2021.
- 36. Shenai MB, Rahme R, Noorchashm H. Equivalency of Protection from Natural Immunity in
- 415 COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis.
- 416 medRxiv 2021:2021.09.12.21263461.
- 417 37. Catherine H. Bozio, Shaun J. Grannis, Allison L. Naleway, et al. Laboratory-Confirmed COVID-
- 418 19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-

421

427

428 429

Induced SARS-CoV-2 Immunity — Nine States, January-September 2021. MMWR Morbidity and 420 Mortality Weekly Report, 2021;70:1539-44. 38. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection 422 with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 2021. MMWR Morb Mortal Wkly 423 Rep 2021;70:1081-3. 424 39. Murugesan M, Prasad M, Hema P, Karthik R, Mammen J, Rupali P. Protective Effect 425 Conferred by Prior Infection and Vaccination on COVID-19 in a Healthcare Worker Cohort in South 426 India. Available at SSRN 2021. 430

Tables and Figures

431

432

433

Table 1: Description of participant demographics, by cohort assignment, June 2020 to September 2021

Demographics	Total n (%)	Naïve cohort n (%)	Positive cohort n (%)	p-value
Gender				
Male	5699 (15.9)	4051 (15.4)	1648 (17.4)	<0.0001
Female	30017 (83.9)	22190 (84.4)	7827 (82.5)	<0.0001
Other	52 (0.1)	39 (0.1)	13 (0.1)	-
Age group				
Under 25	1297 (3.6)	935 (3.6)	362 (3.8)	0.3734
25 to 34	7106 (19.9)	5023 (19.1)	2083 (22.0)	<0.0001
35 to 44	8848 (24.7)	6580 (25.0)	2268 (23.9)	0.0332
45 to 54	10874 (30.4)	8007 (30.5)	2867 (30.2)	0.5861
55 to 64	7085 (19.8)	5283 (20.1)	1802 (19.0)	0.0212
Over 65	558 (1.6)	452 (1.7)	106 (1.1)	<0.0001
Ethnicity				
White	31634 (88.4)	23610 (89.8)	8024 (84.6)	<0.0001
Asian	2486 (7.0)	1581 (6.0)	905 (9.5)	<0.0001
Black	621 (1.7)	381 (1.4)	240 (2.5)	<0.0001
Mixed race	535 (1.5)	380 (1.4)	155 (1.6)	0.1629
Other ethnic group	427 (1.2)	278 (1.1)	149 (1.6)	0.0002
Prefer not to say	65 (0.2)	50 (0.2)	15 (0.2)	-
Medical conditions category				
No medical condition	26670 (74.6)	19569 (74.5)	7101 (74.8)	0.5651
Immunosuppression	803 (2.2)	623 (2.4)	180 (1.9)	0.005
Chronic respiratory conditions	4439 (12.4)	3306 (12.6)	1133 (11.9)	0.0763
Chronic non-respiratory conditions	3856 (10.8)	2782 (10.6)	1074 (11.3)	0.0596
Staff group				
Administrative/Executive (office	5434 (15.2)	4280 (16.3)	1154 (12.2)	
based)	. ,	, ,	, ,	<0.0001
Nursing	12184 (34.1)	8658 (32.9)	3526 (37.2)	<0.0001
Healthcare Assistant	2901 (8.1)	1994 (7.6)	907 (9.6)	<0.0001
Doctor	4248 (11.9)	3053 (11.6)	1195 (12.6)	0.0098
Midwife	777 (2.2)	582 (2.2)	195 (2.1)	0.5669
Physiotherapist/Occupational Therapist/SALT	1438 (4.0)	996 (3.8)	442 (4.7)	0.0001
Estates/Porters/Security	530 (1.5)	389 (1.5)	141 (1.5)	0.0001
Pharmacist	737 (2.1)	582 (2.2)	155 (1.6)	0.0004
Healthcare Scientist	1390 (3.9)	1147 (4.4)	243 (2.6)	<0.0001
Student		, ,		VO.0001
(Medical/Nursing/Midwifery/Other)	1200 (3.4)	867 (3.3)	333 (3.5)	0.3536
Other	4929 (13.8)	3732 (14.2)	1197 (12.6)	0.0001
Occupational setting				
Office based	7002 (19.6)	5481 (20.9)	1521 (16.0)	<0.0001
Patient facing (non-clinical)	1378 (3.9)	1064 (4.0)	314 (3.3)	0.0023
Outpatient	7341 (20.5)	5662 (21.5)	1679 (17.7)	<0.0001

Maternity/Labour Ward	477 (1.3)	361 (1.4)	116 (1.2)	0.1475
Ambulance/Emergency Department/Inpatient Wards	6456 (18.0)	4225 (16.1)	2231 (23.5)	<0.0001
Intensive Care	1669 (4.7)	1273 (4.8)	396 (4.2)	0.0173
Theatres	866 (2.4)	657 (2.5)	209 (2.2)	0.1031
Other	10579 (29.6)	7557 (28.8)	3022 (31.9)	<0.0001
Patient contact				
No	5105 (14.3)	4053 (15.4)	1052 (11.1)	<0.0001
Yes	30663 (85.7)	22227 (84.6)	8436 (88.9)	<0.0001
Frequency of COVID-19 patient contact				
Never	12752 (35.7)	10290 (39.2)	2462 (25.9)	<0.0001
Every day	8797 (24.6)	5585 (21.3)	3212 (33.9)	<0.0001
Once week	6229 (17.4)	4340 (16.5)	1889 (19.9)	<0.0001
Once month	3257 (9.1)	2368 (9.0)	889 (9.4)	0.2457
Less month	4733 (13.2)	3697 (14.1)	1036 (10.9)	<0.0001
Index of Multiple Deprivation				
5 (least deprived)	8871 (24.8)	6563 (25.0)	2308 (24.3)	0.176
4	8073 (22.6)	5982 (22.8)	2091 (22.0)	0.1102
3	7515 (21.0)	5537 (21.1)	1978 (20.8)	0.5387
2	6020 (16.8)	4408 (16.8)	1612 (17.0)	0.6555
1 (most deprived)	3858 (10.8)	2680 (10.2)	1178 (12.4)	<0.0001
Not known	1431 (4.0)	1110 (4.2)	321 (3.4)	0.0006
Geographical area				
East Midlands	2825 (7.9)	1963 (7.5)	862 (9.1)	<0.0001
East of England	3363 (9.4)	2415 (9.2)	948 (10.0)	0.0222
London	3688 (10.3)	2432 (9.3)	1256 (13.2)	<0.0001
North East	647 (1.8)	453 (1.7)	194 (2.0)	0.0582
North West	3429 (9.6)	2174 (8.3)	1255 (13.2)	<0.0001
South East	3548 (9.9)	2568 (9.8)	980 (10.3)	0.1628
South West	5540 (15.5)	4503 (17.1)	1037 (10.9)	<0.0001
West Midlands	2717 (7.6)	1900 (7.2)	817 (8.6)	<0.0001
Yorkshire and Humber	2644 (7.4)	1765 (6.7)	879 (9.3)	<0.0001
Scotland	5449 (15.2)	4646 (17.7)	803 (8.5)	<0.0001
Northern Ireland	1127 (3.2)	888 (3.4)	239 (2.5)	<0.0001
Wales	791 (2.2)	573 (2.2)	218 (2.3)	0.5715
Vaccination status by 21 Sep 21				
2-doses BNT162b2 Long interval	28078 (78.5)	21427 (79.2)	6651 (76.4)	<0.0001
2-doses BNT162b2 Short interval	3059 (8.6)	2493 (9.2)	566 (6.5)	<0.0001
2-doses ChAdOX1	2803 (7.8)	2002 (7.4)	801 (9.2)	<0.0001
1-dose (any)	937 (2.6)	652 (2.4)	285 (3.3)	<0.0001
Unvaccinated	891 (2.5)	483 (1.8)	408 (4.7)	<0.0001
Total	35,768	26,280 (73.5)	9,488 (26.5)	

Positive cohort assignment: 83% seropositive (72% on UKHSA testing), 17% seronegative with historic antibody/PCR positive). Primary infections in the positive cohort occurred in March-May 2020 for 2,576 (57.6%) participants, June-August for 167 (3.7%) and September-December for 1,728 (38.6%). * Index of Multiple Deprivation (IMD), which is a measure of neighbourhood relative deprivation calculated by the Office of National Statistics, was obtained through linkage with participant postcodes

Table 2: Incidence of SARS-CoV-2 infections and effectiveness of COVID-19 vaccines against infection by dose, manufacturer and dosing interval, SIREN participants 07 December 2020 to 21 September 2021

			All infections (symptomatic & asymptomatic)			
Vaccine status	Number of participants	Number of days of follow up	Number of infections	Crude Inciden t rate (per 10,000)	VE (1-HR) 95% CI	aVE (1-HR) 95% CI
Unvaccinated					_ ,	
W ' 4 14 1	24,787	995,122	1067	10.72	Reference	Reference
Vaccinated 1 dose Time since vaccine BNT162b2						
21 – 27 days	21,374	141,696	55	3.88	0.56 (0.40-0.68)	0.57 (0.41-0.69)
28 – 41 days	21,137	279,672	62	2.22	0.62 (0.46-0.74)	0.62 (0.46-0.74)
42 – 55 days	21,968	289,896	32	1.10	0.68 (0.52-0.78)	0.67 (0.51-0.78)
> 55 days	23,049	477,746	60	1.26	0.64 (0.51-0.73)	0.58 (0.42-0.70)
ChAdOX1						
21 – 27 days	2,299	15,848	3	1.89	0.46 (-0.82-0.84)	0.42 (-0.92-0.83)
28 – 41 days	2,423	32,556	1	0.31	0.88 (0.17-0.98)	0.87 (0.10-0.98)
42 – 55 days	2,488	33,514	3	0.90	0.46 (-0.56-0.81)	0.40 (-0.75-0.80)
> 55 days	2,503	64,708	10	1.55	0.36 (-0.30-0.68)	0.29 (-0.43-0.65)
Vaccinated 2 doses Time since vaccine BNT162b2 long- interval						
14 – 73 days	25,571	1,466,353	26	0.18	0.83 (0.70-0.90)	0.81 (0.68-0.89)
74 – 133 days	23,776	1,297,486	285	2.20	0.70 (0.61-0.77)	0.65 (0.56-0.73)
134 – 193 days	18,255	688,494	505	7.33	0.70 (0.61-0.77)	0.67 (0.58-0.75)
>193 days	2,704	24,575	83	33.77	0.43 (0.16-0.61)	0.43 (0.17-0.61)
BNT162b2 short- interval						
14 – 73 days	2,861	151,318	10	0.66	0.85 (0.70-0.92)	0.85 (0.71-0.92)
74 – 133 days	2,822	164,199	6	0.37	0.72 (0.40-0.87)	0.72 (0.42-0.86)
134 – 193 days	2,659	147,301	50	3.39	0.56 (0.38-0.69)	0.55 (0.37-0.67)
>193 days	2,105	84,705	90	10.63	0.59 (0.41-0.71)	0.58 (0.40-0.71)
ChAdOX1						
14 – 73 days	2,394	133,865	19	1.42	0.52 (0.20-0.71)	0.49 (0.16-0.69)
74 – 133 days	2,003	92,621	55	5.94	0.53 (0.34-0.67)	0.47 (0.26-0.63)
> 133 days	995	23,226	32	13.78	0.59 (0.31-0.75)	0.51 (0.18-0.71)

⁴⁴³ Number of infections includes both primary infections and reinfections (all PCR confirmed)

⁴⁴⁴ Crude incident rate: number of infections/days of follow-up (*10,000), does not adjust for variable baseline

⁴⁴⁵ hazard.

VE: unadjusted Vaccine Effectiveness, model adjusted for time since vaccination and previous infection status (time since previous infection).

⁴⁴⁸ aVE: adjusted Vaccine Effectiveness, model adjusted for time since vaccination and previous infection status

^{449 (}time since previous infection) and constant predictors: age, gender, ethnicity, comorbidities, workplace setting,

frequency of contact with COVID-19 patients, geographical area (of workplace). More details are available in

⁴⁵¹ supplementary Table i

medRxiv preprint doi: https://doi.org/10.1101/2021.11.29.21267006; this version posted December 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 3: Incidence of SARS-CoV-2 reinfections and durability of protection against SARS-CoV-2 reinfection, adjusted for vaccine status, in the SIREN cohort between 07 December 2020 and 21 September 2021


Vaccine and prior infection status	Number of participants	Number of days of follow up	Number of infections	Crude incident rate (per 10,000)	Adjusted Absolute protection against infection (1-HR) 95% CI
Unvaccinated					
Naïve	18,039	646,495	983	15.21	Reference
Prior infection 3-9 months	6,173	169,697	41	2.42	0.85 (0.80-0.89)
Prior infection 9-15 months	4,145	163,437	32	1.96	0.85 (0.78-0.89)
Prior infection ≥15 months	291	15,493	11	7.10	0.73 (0.43-0.87
Vaccinated dose 1					
Naive	21,283	1,273,056	607	4.77	0.35 (0.24-0.44
Prior infection 3-9 months	4,561	152,160	15	0.99	0.87 (0.79-0.92
Prior infection 9-15 months	5,978	358,618	24	0.67	0.90 (0.86-0.93
Prior infection ≥15 months	196	7,353	2	2.72	0.87 (0.50-0.97
Vaccinated dose 2					
Naive	22,586	3,414,257	1102	3.23	0.64 (0.56-0.70)
Prior infection 3-9 months	2,928	320,252	24	0.75	0.91 (0.86-0.94
Prior infection 9-15 months	7,202	624,026	29	0.46	0.91 (0.86-0.94
Prior infection ≥15 months	4,980	280,388	30	1.07	0.95 (0.93-0.97

Number of infections includes both primary infections and reinfections (all PCR confirmed)

Crude incident rate: number of infections/days of follow-up (*10,000), does not adjust for variable baseline hazard.

Adjusted absolute protection against infection: model adjusted for previous infection status (time since previous infection), vaccine status (unvaccinated, dose 1 (this includes follow-up between dose 1 and dose 2), dose 2 (includes follow-up after dose 2)) and constant predictors: age, gender, ethnicity, comorbidities, workplace setting, frequency of contact with COVID-19 patients, geographical area (of workplace). Reference group is unvaccinated infection naïve. The model does not adjust for time since vaccination (as in table 2), vaccine manufacturer or vaccine dosing interval, therefore please refer to Table 2 for any vaccine effectiveness estimates.


Figure 1: Adjusted Vaccine Effectiveness over time after two doses: BNT162b2 (Pfizer-BioNTech) short and long interval and ChAdOX1 (combined short and long interval)



Number of participants: **BNT162b2 long-interval**: 14-73 days n=25571, 74-133 days n=23776, 134-193 days n=18255, over 193 days n=2704; **BNT162b2 short-interval**: 14-73 days n=2861, 74-133 days n=2822, 134-193 days n=2659, over 193 days n=2105; **ChAdOx1**: 14-73 days n=2394, 74-133 days n=2003, over 133 days n=995.

aVE: adjusted Vaccine Effectiveness, model adjusted for time since vaccination and previous infection status (time since previous infection) and constant predictors: age, gender, ethnicity, comorbidities, workplace setting, frequency of contact with COVID-19 patients, geographical area (of workplace).

Figure 2: Protection following primary infection under different COVID-19 vaccination scenarios, up to 18 months following infection



Number of participants: **Unvaccinated:** prior infection 3-9 months n=6298, 9-15 months n=4147 and over 15 months n=291; **vaccinated dose 1**: naïve n=21283, prior infection 3-9 months n=4561, 9-15 months n=5978 and over 15 months n=196; **vaccinated dose 2**: naïve n=22586, prior infection 3-9 months n=2928, 9-15 months n=7202 and over 15 months n=4980.

Adjusted absolute protection against infection: model adjusted for previous infection status (time since previous infection), vaccine status (unvaccinated, dose 1 (this includes follow-up between dose 1 and dose 2), dose 2 (includes follow-up after dose 2)) and constant predictors: age, gender, ethnicity, comorbidities, workplace setting, frequency of contact with COVID-19 patients, geographical area (of workplace). Reference group is unvaccinated infection naïve. The model does not adjust for time since vaccination (as in table 2), vaccine manufacturer or vaccine dosing interval.

$^{\square}$ The SIREN study group

Institution	First name	Surname
UK Health Security Agency	Ana	Atti
UK Health Security Agency	Omoyeni	Adebiyi
UK Health Security Agency	Nick	Andrews
UK Health Security Agency	Tim	Brooks
UK Health Security Agency	Colin	Brown
UK Health Security Agency	Davina	Calbraith
UK Health Security Agency	Meera	Chand
· ·	Andre	Charlett
, <u> </u>	Michelle	Cole
i i i	Tom	Coleman
	Joanna	Conneely
i i i i i i i i i i i i i i i i i i i	Paul	Conneely
i i i	Eleanor	Cross
	Silvia	D'Arcangelo
UK Health Security Agency	Sarah	Foulkes
UK Health Security Agency	Nabila	Fowles-Gutierrez
, , ,	Eileen	Gallagher
	Natalie	Gillson
UK Health Security Agency	Victoria	Hall
UK Health Security Agency	Nipu	Hettiarachchi
UK Health Security Agency	Jacqueline	Hewson
UK Health Security Agency	Bethany	Hicks
UK Health Security Agency	Susan	Hopkins
UK Health Security Agency	Kate	Howell
UK Health Security Agency	Ferdinando	Insalata
UK Health Security Agency	Jasmin	Islam
UK Health Security Agency	Jameel	Khawam
UK Health Security Agency	Robert	Kyffin
UK Health Security Agency	Ezra	Linley
UK Health Security Agency	lain	Milligan
UK Health Security Agency	Sebastian	Milward
UK Health Security Agency	Katie	Munro
UK Health Security Agency	Claire	Neill
UK Health Security Agency	Anne-Marie	O'Connell
UK Health Security Agency	Ashley	Otter
UK Health Security Agency	Mary	Ramsay
UK Health Security Agency	Cathy	Rowe
UK Health Security Agency	Ayoub	Saei
UK Health Security Agency	Noshin	Sajedi
UK Health Security Agency	Amanda	Semper
UK Health Security Agency	Andrew	Taylor-Kerr
UK Health Security Agency	Yrene	Themistocleous
UK Health Security Agency	Jean	Timeyin
UK Health Security Agency	Simon	Tonge
UK Health Security Agency	Caio	Tranquillini
UK Health Security Agency	Edgar	Wellington
UK Health Security Agency	Maria	Zambon
	UK Health Security Agency	UK Health Security Agency UK Health Security

48.	Public Health Agency Northern Ireland	Dianne	Corrigan
49.	Public Health Agency Northern Ireland	Lisa	Cromey
50.	Glasgow Caledonian University & Public Health	Lesley	Price
51.	Scotland Glasgow Caledonian University & Public Health	Sally	Stewart
	Scotland		
52.	Glasgow Caledonian University & Public Health Scotland	Nicola	Sergenson
53.	Public Health Scotland	Jennifer	Bishop
54.	Public Health Scotland	Jennifer	Weir
55.	Glasgow Caledonian University	Ayo	Matuluko
56.	Glasgow Caledonian University	Annelysse	Jorgenson
57.	Public Health Scotland	Laura	Dobbie
58.	Public Health Scotland	Andrew	Telfer
59.	Public Health Scotland	David	Goldberg
60.	Public Health Wales	Ellen	De Lacy
61.	Public Health Wales	Guy	Stevens
62.	Public Health Wales	Susannah	Froude
63.	Public Health Wales	Linda	Tyson
64.	Health and Care Research Wales	Yvette	Ellis
65.	Health and Care Research Wales	Chris	Norman
No.	Participating SIREN Sites	First name	Surname
1	ALDER HEY CHILDREN'S NHS FOUNDATION TRUST	В	Larru
		S	Mcwilliam
2	Aneurin Bevan University LHB	John	Northfield
	·	Sean	Cutler
3	ASHFORD AND ST PETER'S HOSPITALS NHS	Stephen	Winchester
	FOUNDATION TRUST	Samuel	Rowley
4	BASILDON AND THURROCK UNIVERSITY	Stacey	Pepper
	HOSPITALS NHS FOUNDATION TRUST	Georgina	Butt
5	BEDFORDSHIRE HOSPITALS NHS FOUNDATION	Simantee	Guha
,	TRUST	Philippa	Bakker
6	Belfast Health & Social Care Trust	Clodagh	Loughrey
_		A	Watt
7	Betsi Cadwaladr University LHB	Christian	Subbe
		Alice	Thomas
8	BIRMINGHAM AND SOLIHULL MENTAL HEALTH	Manny	Bagary
	NHS FOUNDATION TRUST	Di	Baines
9	BIRMINGHAM COMMUNITY HEALTHCARE NHS	Rebecca	Chapman
	FOUNDATION TRUST	Lucy Booth	Booth
10	BLACK COUNTRY HEALTHCARE NHS FOUNDATION	Alison	Grant
	TRUST	Rebecca	Temple-Purcell
11	BLACKPOOL TEACHING HOSPITALS NHS	Joanne	Howard
	FOUNDATION TRUST	Emma	Ward
12	BOLTON NHS FOUNDATION TRUST	Chinari	Subudhi
			= 4.4 4.4.11
	I .	1	+

13	BRIGHTON AND SUSSEX UNIVERSITY HOSPITALS	Marion	Campbell
	NHS TRUST	Andrew	Bexley
14	BUCKINGHAMSHIRE HEALTHCARE NHS TRUST	R	Penn
		N	Wong
15	CALDERDALE AND HUDDERSFIELD NHS	G	Boyd
	FOUNDATION TRUST	Α	Rajgopal
16	CENTRAL AND NORTH WEST LONDON NHS	Abigail	Severn
	FOUNDATION TRUST	R	Matthews
17	CHESTERFIELD ROYAL HOSPITAL NHS	Edward	Harris
	FOUNDATION TRUST	Amanda	Whileman
18	CORNWALL PARTNERSHIP NHS FOUNDATION	Richard	Laugharne
	TRUST	Joanna	Ledger
19	COUNTESS OF CHESTER HOSPITAL NHS	Т	Barnes
	FOUNDATION TRUST	С	Jones
20	CROYDON HEALTH SERVICES NHS TRUST	Banerjee	SubhroOsuji
		Anna	Rokakis
21	Cwm Taf Morgannwg University LHB	John	Geen
		Carla	Pothecary
22	DARTFORD AND GRAVESHAM NHS TRUST	Tracy	Edmunds
		Nihil	Chitalia
23	DERBYSHIRE COMMUNITY HEALTH SERVICES NHS	Sarah	Creer
	FOUNDATION TRUST	Eve	Etell Kirby
24	DERBYSHIRE HEALTHCARE NHS FOUNDATION	S	Akhtar
	TRUST	G	Harrison
25	DEVON PARTNERSHIP NHS TRUST	Clare	McAdam
		Natalie	Crooks
26	DONCASTER AND BASSETLAW TEACHING	K	Agwuh
	HOSPITALS NHS FOUNDATION TRUST	V	Maxwell
27	DORSET COUNTY HOSPITAL NHS FOUNDATION TRUST	Jennifer	Graves
28	DORSET HEALTHCARE UNIVERSITY NHS FOUNDATION TRUST	James	Colton
29	EAST SUFFOLK AND NORTH ESSEX NHS	Α	O'Kelly
	FOUNDATION TRUST	Р	Ridley
30	EAST SUSSEX HEALTHCARE NHS TRUST	Anna	Cowley
		Janet	Sinclair
31	EPSOM AND ST HELIER UNIVERSITY HOSPITALS	Helen	Johnstone
	NHS TRUST	Neringa	Vilimiene
32	FRIMLEY HEALTH NHS FOUNDATION TRUST	Manjula	Meda
		Jane	Democratis
33	GEORGE ELIOT HOSPITAL NHS TRUST	Simon	Brake
		David	Boss
34	GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION	Amanda	Selassie
	TRUST	Rekha Prince	Plackal

			1 .
35	Golden Jubilee National Hospital	Catherine	Sinclair
		Val	Irvine
36	GREAT WESTERN HOSPITALS NHS FOUNDATION TRUST	Eva	Fraile
37	HAMPSHIRE HOSPITALS NHS FOUNDATION	Claire	Thomas
	TRUST	Ina	Hoad
38	HOUNSLOW AND RICHMOND COMMUNITY	Shekoo	Mackay
	HEALTHCARE NHS TRUST	Shivani	Khan
39	HULL UNIVERSITY TEACHING HOSPITALS NHS	Philippa	Burns
	TRUST	Nicholas	Easom
40	Hywel Dda University LHB	Tracy	Lewis
		Zohra	Omar
41	IMPERIAL COLLEGE HEALTHCARE NHS TRUST	Graham	Pickard
		Kenisha	Lewis
42	ISLE OF WIGHT NHS TRUST	Sarah	Hinch
		Alison	Brown
43	JAMES PAGET UNIVERSITY HOSPITALS NHS	Ben	Burton
	FOUNDATION TRUST	Christian	Hacon
44	KING'S COLLEGE HOSPITAL NHS FOUNDATION	Ray	Chaudhuri
	TRUST	Jonnie	Aeron-Thomas
45	LANCASHIRE & SOUTH CUMBRIA NHS	Robert	Shorten
	FOUNDATION TRUST	Kathryn	Williams
46	LANCASHIRE TEACHING HOSPITALS NHS	Maya	Leach
	FOUNDATION TRUST	Robert	Shorten
47	LEEDS TEACHING HOSPITALS NHS TRUST	Kyra	Holliday
		Clair	Favager
48	LEICESTERSHIRE PARTNERSHIP NHS TRUST	Sarah	Baillon
		Samantha	Hamer
49	LEWISHAM AND GREENWICH NHS TRUST	Α	Shah
		J	Russell
50	LINCOLNSHIRE PARTNERSHIP NHS FOUNDATION	Kelly	Moran
	TRUST	Ananta	Dave
51	LIVERPOOL UNIVERSITY HOSPITALS NHS	Anu	Chawla
	FOUNDATION TRUST	Fran	Westwell
52	LONDON NORTH WEST UNIVERSITY HEALTHCARE	Ekaterina	Watson
	NHS TRUST	D	Adeboyeku
53	MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST	С	Pegg
		M	Williams
54	MANCHESTER UNIVERSITY NHS FOUNDATION	S	Ahmad
	TRUST	Α	Horsley
55	MID CHESHIRE HOSPITALS NHS FOUNDATION	Claire	Gabriel
	TRUST	Katherin	Pagett
56	MID ESSEX HOSPITAL SERVICES NHS TRUST	Lauren	Sach
		Yvonne	Lester

57	MID YORKSHIRE HOSPITALS NHS TRUST	Ismaelette	Del Rosario
	A40005151 D0 5V5 + 200515 + 2005 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	John	Ashcroft
58	MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST	Roxanne Chloe	Crosby-Nwaobi Reeks
59	NHS Borders	Joy	Dawson
	AULG E.C	Lauren	Finlayson
60	NHS Fife	Susan	Fowler
<u> </u>	AULC F. d. M. II	Devesh	Dhasmana
61	NHS Forth Valley	Euan	Cameron
		Anne	Todd
62	NHS Grampian	Harriet	Carroll
		Alison	Thornton
63	NHS Greater Glasgow and Clyde	Antonia	Но
		Michael	Murphy
64	NHS Highland	Andrew	Gibson
		Alexandra	Cochrane
65	NHS Lanarkshire	Manish	Patel
		Karen	Black
66	NHS Lothian	Kate	Templeton
		Andrea	Clarke
67	NHS Western Isles	Martin	Malcolm
		Joan	Frieslick
68	NORFOLK AND NORWICH UNIVERSITY HOSPITALS	Ngozi	Elumogo
	NHS FOUNDATION TRUST	Louise	Coke
69	NORTH CUMBRIA INTEGRATED CARE NHS	Beverly	Wilkinson
	FOUNDATION TRUST	John	Elliott
70	NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS	Mariyam	Mirfenderesky
	TRUST	Pratap	Harbham
71	NORTH WEST ANGLIA NHS FOUNDATION TRUST	Janki	Bhayani
		Stephanie	Diaz
72	NORTHERN DEVON HEALTHCARE NHS TRUST	М	Howard
		Т	Lewis
73	NORTHERN HEALTH AND SOCIAL CARE TRUST	Elinor	Hanna
		Frances	Johnston
74	NORTHERN LINCOLNSHIRE AND GOOLE NHS	Jonathan	Hatton
	FOUNDATION TRUST	Peter	Cowling
75	NOTTINGHAM UNIVERSITY HOSPITALS NHS	Sarah	Brand
	TRUST	Imogen	Gould
76	POOLE HOSPITAL NHS FOUNDATION TRUST	Beverley	Wadams
		Elizabeth	Sheridan
77	PORTSMOUTH HOSPITALS NHS TRUST	Johanna	Mouland
		Jade	Yates
78	Powys Teaching LHB	Jayne	Goodwin
		Chris	Norman

79	QUEEN VICTORIA HOSPITAL NHS FOUNDATION TRUST	J	Giles
		G	Pottinger
80	ROYAL BERKSHIRE NHS FOUNDATION TRUST	Maya	Joseph
		Holly	Coles
81	ROYAL CORNWALL HOSPITALS NHS TRUST	H	Chenoweth
		D	Browne
82	ROYAL DEVON AND EXETER NHS FOUNDATION	Cressida	Auckland
	TRUST	Stephanie	Prince
83	ROYAL FREE LONDON NHS FOUNDATION TRUST	Alison	Rodger
		Tabitha	Mahungu
84	ROYAL NATIONAL ORTHOPAEDIC HOSPITAL NHS	Esther	Hanison
	TRUST	Simon	Warren
85	ROYAL PAPWORTH HOSPITAL NHS FOUNDATION	Sumita	Pai
	TRUST	Helen	Baxendale
86	ROYAL SURREY COUNTY HOSPITAL NHS	Charles	Piercy
	FOUNDATION TRUST	Esther	Tarr
87	ROYAL UNITED HOSPITALS BATH NHS	Debbie	Delgado
	FOUNDATION TRUST	Sarah	Meisner
88	SALISBURY NHS FOUNDATION TRUST	Catherine	Thompson
		Sophia	Strong-Sheldrake
89	SANDWELL AND WEST BIRMINGHAM HOSPITALS	Ash	Turner
	NHS TRUST	Anne	Hayes
90	SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST	S	Gormley
		С	Kerrison
91	SHEFFIELD TEACHING HOSPITALS NHS	Thushan	de Silva
	FOUNDATION TRUST	Simon	Tazzyman
92	SHERWOOD FOREST HOSPITALS NHS	Lynne	Allsop
	FOUNDATION TRUST	Shrikant	Ambalkar
93	SHREWSBURY AND TELFORD HOSPITAL NHS	Mandy	Beekes
	TRUST	Hannah	Gibson
94	SHROPSHIRE COMMUNITY HEALTH NHS TRUST	Johanne	Tomlinson
95	SOLENT NHS TRUST	Cathy	Price
		The Solent	
		Research	
		Team	
96	SOMERSET NHS FOUNDATION TRUST	Justin	Pepperell
		Kate	James
97	South Eastern Health & Social Care	Yuri	Protaschik
	South Eastern Health & Social Care	Tom	Trinick
98	SOUTHEND UNIVERSITY HOSPITAL NHS	John	Day
	FOUNDATION TRUST	Swapna	Kunhunny
99	Southern Health & Social Care Trust	Angel	Boulos
		Alice	Neave
100	SOUTHERN HEALTH NHS FOUNDATION TRUST	Qi	Zheng

101	SOUTHPORT AND ORMSKIRK HOSPITAL NHS	Katherine	Gray
	TRUST	Kerryanne	Brown
102	ST GEORGE'S UNIVERSITY HOSPITALS NHS	Tim	Planche
	FOUNDATION TRUST	Angela	Houston
103	ST HELENS AND KNOWSLEY TEACHING	Rowan	Pritchard Jones
_	HOSPITALS NHS TRUST	Diane	Wycherley
104	STOCKPORT NHS FOUNDATION TRUST	Barzo	Faris
105	SURREY AND SUSSEX HEALTHCARE NHS TRUST	К	Nimako
		В	Stewart
106	Swansea Bay University LHB	Claire	Stafford
		Rebeccah	Thomas
107	THE CLATTERBRIDGE CANCER CENTRE NHS	Sheena	Khanduri
	FOUNDATION TRUST	Nagesh	Kalakonda
108	THE DUDLEY GROUP NHS FOUNDATION TRUST	Helen	Ashby
109	THE HILLINGDON HOSPITALS NHS FOUNDATION TRUST	Natasha	Mahabir
110	THE NEWCASTLE UPON TYNE HOSPITALS NHS	J	Harwood
	FOUNDATION TRUST	В	Payne
111	THE PRINCESS ALEXANDRA HOSPITAL NHS TRUST	Kathryn	Court
		Nikki	White
112	THE ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL NHS FOUNDATION TRUST	Ruth	Longfellow
113	THE ROYAL BOURNEMOUTH AND CHRISTCHURCH HOSPITALS NHS FOUNDATION TRUST	Mihye	Lee
114	THE ROYAL WOLVERHAMPTON NHS TRUST	Marie	Green
		Lauren	Hughes
115	TORBAY AND SOUTH DEVON NHS FOUNDATION	Mathew	Halkes
	TRUST	Pauline	Mercer
116	UNITED LINCOLNSHIRE HOSPITALS NHS TRUST	Alun	Roebuck
			ULHT Research
			Team
117	UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST	E	Wilson-Davies
118	UNIVERSITY HOSPITALS BRISTOL AND WESTON	Rajeka	Lazarus
	NHS FOUNDATION TRUST	Aaran	Sinclair
119	UNIVERSITY HOSPITALS COVENTRY AND	N	Aldridge
	WARWICKSHIRE NHS TRUST	L	Berry
120	UNIVERSITY HOSPITALS OF DERBY AND BURTON	F	Game
	NHS FOUNDATION TRUST	Т	Reynolds
121	UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST	Christopher	Holmes
		Martin	Wiselka
122	UNIVERSITY HOSPITALS OF MORECAMBE BAY	Lynda	Fothergill
	NHS FOUNDATION TRUST	Karen	Burns
			1

123	UNIVERSITY HOSPITALS OF NORTH MIDLANDS	Christopher	Duff
	NHS TRUST	Martin	Booth
124	UNIVERSITY HOSPITALS PLYMOUTH NHS TRUST	Hannah	Jory
		David	Hilton
125	Velindre NHS Trust	Charlotte	Young
		James	Powell
126	WALSALL HEALTHCARE NHS TRUST	Lisa	Richardson
		Aiden	Plant
127	WARRINGTON AND HALTON TEACHING	Zaman	Qazzafi
	HOSPITALS NHS FOUNDATION TRUST	Lisa	Ditchfield
128	WEST SUFFOLK NHS FOUNDATION TRUST	Α	Moody
		R	Tilley
129	Western Health & Social Care Trust	Tracy	Donaghy
		Maurice	O'Kane
130	WESTERN SUSSEX HOSPITALS NHS FOUNDATION	R	Sierra
	TRUST	K	Shipman
131	WHITTINGTON HEALTH NHS TRUST	Philippa	Kemsley
132	WIRRAL UNIVERSITY TEACHING HOSPITAL NHS	D	Harvey
132	FOUNDATION TRUST	Y	Huang
133	WYE VALLEY NHS TRUST	L	Robinson
134	YEOVIL DISTRICT HOSPITAL NHS FOUNDATION	Sarah	Board
134	TRUST	Andrew	Broadley
425		_	Brookes
135	YORK TEACHING HOSPITAL NHS FOUNDATION TRUST	Claire	
	111031	Mags	Szewczyk
No.	SIREN Associated Studies	First name	Surname
1.	Protective Immunity from T cells to Covid-19 in Health workers (PITCH)	Susie	Dunachie
2.	Protective Immunity from T cells to Covid-19 in Health workers (PITCH)	Paul	Klenerman
3.	Protective Immunity from T cells to Covid-19 in Health workers (PITCH)	Chris	Duncan
4.	Protective Immunity from T cells to Covid-19 in Health workers (PITCH)	Lance	Turtle
5.	Protective Immunity from T cells to Covid-19 in Health workers (PITCH)	Alex	Richter
6.	Protective Immunity from T cells to Covid-19 in Health workers (PITCH)	Thushan	De Silva
7.	Protective Immunity from T cells to Covid-19 in Health workers (PITCH)	Eleanor	Barnes
8.	Protective Immunity from T cells to Covid-19 in Health workers (PITCH)	Daniel	Wootton
9.	The Humoral Immune Correlates for COVID- 19 (HICC) consortium	Jonathan	Heeney
10.	The Humoral Immune Correlates for COVID-19 (HICC) consortium	Helen	Baxendale

11.	The Humoral Immune Correlates for COVID-19 (HICC) consortium	Javier	Castillo-Olivares
12.	The Francis Crick Institute	Rupert	Beale
13.	The Francis Crick Institute	Edward	Carr
14.	Genotype2Phenotype (G2P)	Wendy	Barclay
15.	Genotype2Phenotype (G2P)	Massimo	Palmarini
16.	GenOMICC	John	Baillie
		Kenneth	